E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
Tapan M. Kadia,Stefan Faderl,Farhad Ravandi,Elias Jabbour,Guillermo Garcia-Manero,Gautam Borthakur,Alessandra Ferrajoli,Marina Konopleva,Jan A. Burger,Xuelin Huang,Xuemei Wang,Sherry Pierce,Mark Brandt,Jennie Feliu,Jorge E. Cortes,Hagop M. Kantarjian +15 more
TL;DR: The treatment of older adults with acute myeloid leukemia using standard intensive chemotherapy has been associated with poor outcomes and effective, less toxic therapies are needed to achieve and maintain durable remissions.
Journal ArticleDOI
Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
Giuseppe Saglio,Hagop M. Kantarjian,Neil P. Shah,Elias Jabbour,Alfonso Quintás-Cardama,Juan Luis Steegmann,Concepción Boqué,Charles Chuah,Carolina Pavlovsky,Jiri Mayer,Jon A. Ukropec,Mark Wildgust,Andreas Hochhaus +12 more
TL;DR: More pts treated with dasatinib achieved a faster, deeper cytogenetic and molecular response, which was associated with better 3-y outcomes and lower risk of transformation to AP/BP, and the clinical importance of achieving deeper levels of cytogenic response (CCyR) at 6 mo will be presented.
Journal ArticleDOI
High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.
Chi Young Ok,L. Jeffrey Medeiros,Beenu Thakral,Guilin Tang,Nitin Jain,Elias Jabbour,Sherry Pierce,Sergej Konoplev +7 more
TL;DR: In patients with TdT-positive aggressive B-cell lymphoma, the cytogenetic findings and poor prognosis suggest that these neoplasms need to be distinguished from B-lymphoblastic leukemia/lymphoma.
Journal ArticleDOI
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Naval Daver,Guillermo Garcia-Manero,Marina Konopleva,Mansour Alfayez,Naveen Pemmaraju,Tapan M. Kadia,Courtney D. DiNardo,Jorge E. Cortes,Farhad Ravandi,Hussein A. Abbas,Sreyashi Basu,Elias Jabbour,Sherry Pierce,Zeev Estrov,Koichi Takahashi,Jing Ning,Steven M. Kornblau,Koji Sasaki,Lucia Masarova,Wilmer Flores,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +22 more
TL;DR: Responsibility rates and OS were superior to contemporary historic HMA-based clinical trial controls at MDACC, suggesting progressive T-cell exhaustion with multiple relapses may be a major hindrance to successful T- cell based therapies.
Journal ArticleDOI
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
Hagop M. Kantarjian,Yun Su,Elias Jabbour,H. Bhattacharyya,Eric Yan,Joseph C. Cappelleri,David I. Marks +6 more
TL;DR: Inotuzumab ozogamicin (InO), an anti‐CD22 antibody‐calicheamicin conjugate, demonstrated superior clinical activity versus standard‐of‐care (SOC) chemotherapies for relapsed/refractory B‐cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO‐VATE trial.